Suppr超能文献

双能 X 射线吸收法评估黏多糖贮积症患者的骨密度。

Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses.

机构信息

Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.

出版信息

Orphanet J Rare Dis. 2013 May 11;8:71. doi: 10.1186/1750-1172-8-71.

Abstract

BACKGROUND

Patients with mucopolysaccharidoses (MPS) are associated with poor bone growth and mineralization, however, information regarding the assessment of bone mineral density (BMD) in relation to age and treatment in this disorder is limited.

METHODS

Dual energy x-ray absorptiometry (DXA) was performed in 30 patients with MPS (21 males and 9 females; 2 with MPS I, 12 with MPS II, 2 with MPS IIIB, 9 with MPS IVA, and 5 with MPS VI; median age, 10.8 years; age range, 5.0 years to 23.7 years; 26 patients were under 19 and 4 were above 19 years of age) to assess BMD of the lumbar spine (L1-L4), using the Hologic QDR 4500 system (Bedford, MA, USA).

RESULTS

For 26 patients under 19 years of age, standard deviation scores (z scores) for height, weight, body mass index (BMI), and BMD were -4.53 ± 2.66, -1.15 ± 1.55, 0.74 ± 1.23, and -3.03 ± 1.62, respectively, and they were all negatively correlated with age (p < 0.05). However, after correction for height-for-age z score (HAZ), HAZ adjusted BMD z score was -0.7 ± 1.24. Eight patients (31%) had osteopenia (HAZ adjusted BMD z score < -1 and ≥ -2), and 4 patients (15%) had osteoporosis (HAZ adjusted BMD z score < -2). Of 8 patients with MPS I, II or VI who underwent follow-up DXA after receiving enzyme replacement therapy for 1.0 to 7.4 years, all showed increase in absolute BMD values.

CONCLUSIONS

These findings and the follow-up data can be used to develop quality of care strategies for patients with MPS.

摘要

背景

黏多糖贮积症(MPS)患者的骨骼生长和矿化不良,然而,该疾病中关于骨密度(BMD)与年龄和治疗关系的评估信息有限。

方法

对 30 名 MPS 患者(21 名男性,9 名女性;2 名 MPS I 型,12 名 MPS II 型,2 名 MPS IIIB 型,9 名 MPS IVA 型,5 名 MPS VI 型;中位年龄 10.8 岁;年龄范围 5.0 岁至 23.7 岁;26 名患者年龄在 19 岁以下,4 名患者年龄在 19 岁以上)进行双能 X 射线吸收法(DXA)检查,使用 Hologic QDR 4500 系统(美国马萨诸塞州贝德福德)评估腰椎(L1-L4)的 BMD。

结果

对于 26 名年龄在 19 岁以下的患者,身高、体重、体重指数(BMI)和 BMD 的标准偏差评分(z 评分)分别为-4.53±2.66、-1.15±1.55、0.74±1.23 和-3.03±1.62,均与年龄呈负相关(p<0.05)。然而,经过身高年龄 z 评分(HAZ)校正后,HAZ 调整的 BMD z 评分则为-0.7±1.24。8 名患者(31%)存在骨质疏松症(HAZ 调整的 BMD z 评分<-1 且≥-2),4 名患者(15%)存在骨质疏松症(HAZ 调整的 BMD z 评分<-2)。8 名接受酶替代治疗 1.0 至 7.4 年的 MPS I、II 或 VI 型患者进行了随访 DXA,所有患者的绝对 BMD 值均增加。

结论

这些发现和随访数据可用于制定 MPS 患者的护理质量策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2aa/3698009/514da222f810/1750-1172-8-71-1.jpg

相似文献

3
Evaluation of bone health in patients with mucopolysaccharidosis.
J Bone Miner Metab. 2022 May;40(3):498-507. doi: 10.1007/s00774-021-01304-4. Epub 2022 Jan 23.
4
Bone mineral density in patients with mucopolysaccharidosis type III.
J Bone Miner Metab. 2017 May;35(3):338-343. doi: 10.1007/s00774-016-0762-y. Epub 2016 May 18.
5
Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children.
J Clin Endocrinol Metab. 2010 Mar;95(3):1265-73. doi: 10.1210/jc.2009-2057. Epub 2010 Jan 26.
6
Bone health of children with intestinal failure measured by dual energy X-ray absorptiometry and digital X-ray radiogrammetry.
Clin Nutr. 2018 Apr;37(2):687-694. doi: 10.1016/j.clnu.2017.02.014. Epub 2017 Feb 21.
7
Dual-energy CT-based phantomless in vivo three-dimensional bone mineral density assessment of the lumbar spine.
Radiology. 2014 Jun;271(3):778-84. doi: 10.1148/radiol.13131952. Epub 2014 Jan 16.
8
Radiographic Findings of Mucopolysaccharidosis and Comparison with Bone Mineral Density: A Study from Southeastern Turkey.
J Clin Densitom. 2022 Oct-Dec;25(4):475-484. doi: 10.1016/j.jocd.2022.08.001. Epub 2022 Aug 18.
9
Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome.
Osteoporos Int. 2004 Nov;15(11):855-61. doi: 10.1007/s00198-004-1616-3. Epub 2004 Mar 18.
10
Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area.
J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):276-80. doi: 10.1097/00005176-200403000-00008.

引用本文的文献

1
Femoral Structure and Biomechanical Characteristics in Sanfilippo Syndrome Type-B Mice.
Int J Mol Sci. 2023 Sep 12;24(18):13988. doi: 10.3390/ijms241813988.
3
Mucopolysaccharidosis: What Pediatric Rheumatologists and Orthopedics Need to Know.
Diagnostics (Basel). 2022 Dec 27;13(1):75. doi: 10.3390/diagnostics13010075.
4
MPSI Manifestations and Treatment Outcome: Skeletal Focus.
Int J Mol Sci. 2022 Sep 22;23(19):11168. doi: 10.3390/ijms231911168.
6
Non-cardiac Manifestations in Adult Patients With Mucopolysaccharidosis.
Front Cardiovasc Med. 2022 Mar 7;9:839391. doi: 10.3389/fcvm.2022.839391. eCollection 2022.
7
Evaluation of bone health in patients with mucopolysaccharidosis.
J Bone Miner Metab. 2022 May;40(3):498-507. doi: 10.1007/s00774-021-01304-4. Epub 2022 Jan 23.
8
Progression of vertebral bone disease in mucopolysaccharidosis VII dogs from birth to skeletal maturity.
Mol Genet Metab. 2021 Aug;133(4):378-385. doi: 10.1016/j.ymgme.2021.06.005. Epub 2021 Jun 15.
9
Failures of Endochondral Ossification in the Mucopolysaccharidoses.
Curr Osteoporos Rep. 2020 Dec;18(6):759-773. doi: 10.1007/s11914-020-00626-y. Epub 2020 Oct 16.

本文引用的文献

1
Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Pediatr Pulmonol. 2014 Mar;49(3):277-84. doi: 10.1002/ppul.22774. Epub 2013 Feb 8.
2
Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.
J Inherit Metab Dis. 2013 Mar;36(2):235-46. doi: 10.1007/s10545-012-9522-x. Epub 2012 Sep 13.
3
Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.
J Inherit Metab Dis. 2013 Jan;36(1):123-7. doi: 10.1007/s10545-012-9503-0. Epub 2012 Jun 21.
4
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).
J Inherit Metab Dis. 2013 Mar;36(2):373-84. doi: 10.1007/s10545-011-9410-9. Epub 2011 Nov 30.
5
Therapeutic approaches to bone pathology in Gaucher disease: past, present and future.
Mol Genet Metab. 2011 Dec;104(4):438-47. doi: 10.1016/j.ymgme.2011.08.004. Epub 2011 Aug 11.
6
Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.
Medicine (Baltimore). 2011 Jan;90(1):52-60. doi: 10.1097/MD.0b013e3182057be4.
7
Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.
Genet Med. 2011 Feb;13(2):95-101. doi: 10.1097/GIM.0b013e3181fea459.
8
Enzyme replacement therapy for mucopolysaccharidosis VI--experience in Taiwan.
J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S421-7. doi: 10.1007/s10545-010-9212-5. Epub 2010 Oct 6.
10
Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density.
Bone. 2010 Sep;47(3):643-9. doi: 10.1016/j.bone.2010.06.021. Epub 2010 Jun 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验